Actinium Pharma Advances Solid-Tumor Program With Phase 1 Clinical Trial In South Africa Targeting B7-H3

Actinium Pharmaceuticals (NYSE:ATNM), a company developing targeted alpha radiotherapies, is advancing its solid-tumor program with a Phase 1 clinical trial in South Africa targeting B7-H3. This study represents one of the earliest clinical explorations of the company's ATNM-400 platform, which uses the alpha-emitting isotope Actinium-225 (Ac-225) to deliver highly potent radiation directly to cancer cells.

The South African trial marks a meaningful development step at a time when interest in radiopharmaceuticals is accelerating globally. As oncology researchers and investors look for treatment options capable of overcoming resistance in late-stage cancers, alpha-based radiotherapy programs like ATNM-400 have entered the spotlight.